Sivelestat (ONO-5046, 0.021-2.1 mg/kg, intratracheally) suppresses lung hemorrhage in hamster (ID50 = 82 pg/kg) by intratracheal administration and increase of skin capillary permeability in guinea pig (ID50 = 9.6 mg/kg) by intravenous administration, both of which are induced by human neutrophil elastase[1].
Sivelestat (10 mg/kg, infusion via the tail vein) ameliorates lung injury after hemorrhagic shock in rats[2].
Sivelestat (15, 60 mg/kg, ip) prevents ischemia–reperfusion injury in the rat bladder[3].
| Animal Model: | Male Golden hamsters, weighing 90 to 110 g[1]. |
| Dosage: | 0.021-2.1 mg/kg. |
| Administration: | Intratracheally five min before HNE injection. |
| Result: | Significantly and dosedependently suppressed the lung hemorrhage. |
| Animal Model: | Male Sprague-Dawley rats weighing 350-400 g[2]. |
| Dosage: | 10 mg/kg. |
| Administration: | Continuous infusion via the tail vein at 10 mg/kg/h for 60 min during the resuscitation phase. |
| Result: | Greatly suppressed lung injury, as revealed by the reduced histological damage.
Significantly ameliorated HSR-induced lung injury.
Markedly decreased the levels of TNF-α and iNOS gene.
|
| Animal Model: | Male Sprague Dawley rats, 8 weeks old and weighing 250-320 g[3]. |
| Dosage: | 15 mg/kg or 60 mg/kg. |
| Administration: | IP. |
| Result: | Decreased the blood flow in the bladder during reperfusion phase compared to the IR group. |
![N-[2-[[[4-(2,2-Dimethyl-1-oxopropoxy)phenyl]sulfonyl]amino]benzoyl]-(S)-glycine monosodium salt Structure](/CAS/GIF/150374-95-1.gif)
